Boston Children’s launches genomics venture

Editorial Staff | | Health Exec | Economics

Boston Children’s Hospital has partnered with Life Technologies to launch Claritas Genomics, a new company formed to develop genetic and genomics-based diagnostic testing technologies.

The venture will combine instrumentation, software and bioinformatics capabilities with clinical interpretation of test results and consultation by physicians and medical genomics experts at Boston Children’s Hospital.

Claritas Genomics, majority owned by Children’s, will incorporate the expertise, assets and personnel of the hospital’s Genetic Diagnostic Lab, a CLIA-certified center that offers more than 100 genetic tests. It will leverage Life Technologies’ Ion Proton Sequencer, a benchtop technology that can be scaled for mass application for new tests that the company plans to develop.

Claritas Genomics will seek to validate the Ion Proton Sequencer’s clinical utility and tests developed on the platform for clinical use. The new company also is developing relationships with other U.S. and international children’s hospitals to create a network of pediatric academic centers that can share data, especially important for rare diseases that require large numbers of patients to discover genetic markers.

Editorial Staff

Related Content

Cardiologist demand is on the rise—can hospitals keep up?
Cardinal Health scoops up two companies for $3.9B
UnitedHealth defends $3.3B Amedisys acquisition
DOJ sues to block UnitedHealth’s $3.3B acquisition of home health giant
Private equity firm to buy Summa Health for $485M
Private equity transactions in healthcare down 15% since 2023, report finds

Around the web

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

Cardiovascular Business
FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Design by Adaptive Theme
Trimed Popup
Trimed Popup